⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MLTX News
MoonLake Immunotherapeutics Class A Ordinary Shares
Form 8-K
sec.gov
MLTX
Form 8-K
sec.gov
MLTX
MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
globenewswire.com
MLTX
MoonLake Immunotherapeutics Announces Proposed Public Offering
globenewswire.com
MLTX
Form 8-K
sec.gov
MLTX
MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
globenewswire.com
MLTX
Form 8-K
sec.gov
MLTX
Form 8-K
sec.gov
MLTX
Form 8-K
sec.gov
MLTX
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
globenewswire.com
MLTX